Advances in mRNA & LNP technology for in vivo CAR-T therapy, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how advances in mRNA design and lipid nanoparticle (LNP) technology can support direct in vivo CAR-T cell engineering. The featured speaker will discuss CAR construct design, RNA modifications and targeted LNP approaches aimed at improving expression, durability and T cell-specific delivery. Attendees will also explore how these technologies can support more precise and flexible in vivo CAR-T development.

TORONTO, Oct. 22, 2026 /PRNewswire/ -- In vivo CAR-T therapy requires durable, yet transient CAR expression coupled with efficient, T cell-specific delivery. This webinar will focus on how innovations in RNA design and next-generation lipid nanoparticle (LNP) technology are enabling direct in vivo engineering of T cells, replacing conventional ex vivo manufacturing. This webinar will explore key advances in CAR construct design and novel LNP formulations to improve the precision, potency and safety of in vivo CAR-T therapies.

Modular "drop-in" CAR plasmids that streamline both construct design and RNA production will be introduced. These vectors produce mRNAs optimized for CAR expression and support flexible swapping of antigen-binding domains, enabling rapid screening and efficient customization. This approach may be particularly useful for researchers who are new to CAR-T development.

The featured speaker will present recent innovations in RNA design to enhance expression, durability and tissue specificity. These innovations include a modified poly(A) tail that improves transcript stability and translational efficiency and a T cell-specific internal ribosome entry site (IRES) that, when incorporated into circular RNA (circRNA), restricts CAR expression to T cells and reduces off-target effects.

This session will also highlight novel LNP technology engineered for T cell-directed delivery, including exosome-like and spleen-tropic LNPs that enrich delivery to lymphoid tissues where T cells are concentrated and improve CAR expression. VHH site-specific conjugated LNPs that employ single-domain antibody fragments for precise T cell targeting will also be discussed. Collectively, these advances in CAR construct design, RNA engineering and targeted LNP systems represent a comprehensive toolbox for next-generation in vivo CAR-T therapy development.

Register for this webinar to learn how LNP technology can support targeted RNA delivery and in vivo CAR-T cell engineering.

Join Mark Shulewitz, PhD, Field Application Scientist, GenScript, for the live webinar on Thursday, November 5, 2026, at 11am EST (5pm CET / EU-Central).

For more information, or to register for this event, visit Advances in mRNA & LNP technology for in vivo CAR-T therapy.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks